[Cutaneous side effects of targeted cancer drugs]. (Q53193539)

12 May 2018

review article

1 reference

title

[Cutaneous side effects of targeted cancer drugs]. (English)

1 reference

12 May 2018

author name string

J Below

series ordinal

1

1 reference

12 May 2018

B Homey

series ordinal

2

1 reference

12 May 2018

P A Gerber

series ordinal

3

1 reference

12 May 2018

language of work or name

German

0 references

publication date

1 January 2017

1 reference

12 May 2018

published in

Die Dermatologie

1 reference

12 May 2018

volume

68

1 reference

12 May 2018

issue

1

1 reference

12 May 2018

page(s)

12-18

1 reference

12 May 2018

Sunitinib induced pyoderma gangrenosum-like ulcerations

cites work

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Mechanisms of skin aging induced by EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Images in clinical medicine. Erlotinib-induced hair alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

New and emerging targeted treatments in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Analysis of dermatologic events in vemurafenib-treated patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Ipilimumab in patients with cancer and the management of dermatologic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Epidermal EGFR controls cutaneous host defense and prevents inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

[Systemic therapy for malignant melanoma].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Immunolocalization of Epidermal Growth Factor Receptors in Normal Developing Human Skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Improved overall survival in melanoma with combined dabrafenib and trametinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Skin toxicities of targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Incidence of new primary melanomas after diagnosis of stage III and IV melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00105-016-3902-3

Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?

21 January 2018

1 reference

12 December 2020

Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma

1 reference

12 December 2020

Ultraviolet A and photosensitivity during vemurafenib therapy

1 reference

12 December 2020

Side effects of systemic oncological therapies in dermatology

1 reference

12 December 2020

The hand-foot-syndrome associated with medical tumor therapy - classification and management

1 reference

12 December 2020

Bridging academic science and clinical research in the search for novel targeted anti-cancer agents

1 reference

12 December 2020

Severe cutaneous reaction during radiation therapy with concurrent cetuximab

1 reference

12 December 2020

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies

1 reference

12 December 2020

Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician

1 reference

12 December 2020

Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer

1 reference

12 December 2020

Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects

1 reference

12 December 2020

Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib

1 reference

12 December 2020

10.1007/S00105-016-3902-3

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018